Rifki Ucler1, Mehmet Aslan2, Murat Atmaca1, Murat Alay1, Esra Nur Ademoglu3, Zehra Candan4, Ismail Gulsen5. 1. Department of Endocrinology and Metabolism, Medical Faculty, Yuzuncu Yil University Van, Turkey. 2. Department of Internal Medicine, Medical Faculty, Yuzuncu Yil University Van, Turkey. 3. Department of Endocrinology and Metabolism, Bitlis State Hospital Bitlis, Turkey. 4. Department of Endocrinology and Metabolism, Van Education and Research Hospital Van, Turkey. 5. Department of Neurosurgery, Medical Faculty, Yuzuncu Yil University Van, Turkey.
Abstract
OBJECTIVES: Several studies have shown increased atherogenic risk factors and biomarkers of inflammation and atherosclerosis in association with growth hormone excess. Mean platelet volume (MPV) and red blood cell distribution (RDW) are currently gaining interest as new independent cardiovascular risk factors. The aim of this study was to evaluate the effect of disease control on MPV and RDW in acromegaly patients. MATERIALS AND METHODS: We retrospectively enrolled 36 acromegaly patients (23 males, 13 females; mean age 41.94 ± 11.55). Patients were divided into two groups: disease controlled by surgical treatment alone (group A) or by somatostatin analog (SSA) therapy (group B). MPV and RDW measurements were evaluated during active and inactive disease periods in the two groups. RESULTS: There were statistically significant increases in MPV and RDW in patients receiving SSA therapy (P = 0.012 and P = 0.020, respectively). The differences in MPV and RDW changes in patients receiving surgical treatment alone were not statistically significant (P=0.364 and P=0.339, respectively). CONCLUSIONS: This is the first report on the evaluated the effect of disease control on MPV and RDW in acromegaly patients. Our study results showed that MPV and RDW measurements are significantly increased in acromegaly patients with disease controlled by SSA therapy. Therefore, acromegalic patients treated with SSAs may have increased cardiovascular risk based on an increase in MPV and RDW.
OBJECTIVES: Several studies have shown increased atherogenic risk factors and biomarkers of inflammation and atherosclerosis in association with growth hormone excess. Mean platelet volume (MPV) and red blood cell distribution (RDW) are currently gaining interest as new independent cardiovascular risk factors. The aim of this study was to evaluate the effect of disease control on MPV and RDW in acromegalypatients. MATERIALS AND METHODS: We retrospectively enrolled 36 acromegalypatients (23 males, 13 females; mean age 41.94 ± 11.55). Patients were divided into two groups: disease controlled by surgical treatment alone (group A) or by somatostatin analog (SSA) therapy (group B). MPV and RDW measurements were evaluated during active and inactive disease periods in the two groups. RESULTS: There were statistically significant increases in MPV and RDW in patients receiving SSA therapy (P = 0.012 and P = 0.020, respectively). The differences in MPV and RDW changes in patients receiving surgical treatment alone were not statistically significant (P=0.364 and P=0.339, respectively). CONCLUSIONS: This is the first report on the evaluated the effect of disease control on MPV and RDW in acromegalypatients. Our study results showed that MPV and RDW measurements are significantly increased in acromegalypatients with disease controlled by SSA therapy. Therefore, acromegalicpatients treated with SSAs may have increased cardiovascular risk based on an increase in MPV and RDW.
Authors: Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller Journal: Endocr Pract Date: 2011 Jul-Aug Impact factor: 3.443
Authors: G Avramakis; E Papadimitraki; D Papakonstandinou; K Liakou; M Zidianakis; A Dermitzakis; D P Mikhailidis; E S Ganotakis Journal: Platelets Date: 2007-02 Impact factor: 3.862
Authors: Giuseppe Lippi; Gian Luca Salvagno; Antonio Nouvenne; Tiziana Meschi; Loris Borghi; Giovanni Targher Journal: Prim Care Diabetes Date: 2014-09-22 Impact factor: 2.459
Authors: M Demirpence; H Y Yasar; A Colak; B Akinci; S Yener; B Toprak; I Karademirci Journal: Acta Endocrinol (Buchar) Date: 2016 Oct-Dec Impact factor: 0.877